If you have been reading about reversed-phase chromatography and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
=== 10 January === Ukrainian steel production was reduced by about 70% in 2022 as a result of the conflict. US and Ukrainian officials stated that Russian artillery fire had declined nearly 75% in some places. The UK said most of Soledar was under Russian control, whereas Wagner claimed all.
==== Other parameters ==== Advanced hematology analyzers generate novel measurements of blood cells which have shown diagnostic significance in research studies but have not yet found widespread clinical use. For example, some types of analyzers produce coordinate readings indicating the size and position of each white blood cell cluster. These parameters (termed cell population data) have been studied as potential markers for blood disorders, bacterial infections and malaria. Analyzers that use myeloperoxidase staining to produce differential counts can measure white blood cells' expression of the enzyme, which is altered in various disorders. Some instruments can report the percentage of red blood cells that are hypochromic in addition to reporting the average MCHC value, or provide a count of fragmented red cells (schistocytes), which occur in some types of hemolytic anemia. Because these parameters are often specific to particular brands of analyzers, it is difficult for laboratories to interpret and compare results.
==== United States ==== Pentazocine was originally unclassified under the Controlled Substances Act in the United States. A petition was filed with the US Drug Enforcement Administration (DEA) on October 1, 1971, to shift it to Schedule III. The petition was filed by Joseph L. Fink III, a pharmacist and law student at Georgetown University Law Center as part of the course Lawyering in the Public Interest. That petition was accepted for review on November 10, 1971. The DEA published a Final Rule transferring it to Schedule IV on January 10, 1979, with an effective date of February 9, 1979. Pentazocine is still classified in Schedule IV under the Controlled Substances Act in the United States, even with the addition of naloxone. Some states classify it in Schedule II, such as Illinois and South Carolina (injectable form only), or Schedule III such as Kentucky.) Internationally, pentazocine is a Schedule III drug under the Convention on Psychotropic Substances, except in Canada where it is Schedule I under the federal Controlled Drugs and Substances Act. Pentazocine has a DEA ACSCN of 9720; being a Schedule IV substance, the DEA does not assign an annual manufacturing quota for pentazocine for the United States.
=== Disorders of consciousness === Selegiline has been studied in patients with disorders of consciousness, such as minimally conscious state, persistent vegetative state, and persistent coma, in a small open-label clinical study. It was found to be effective in enhancing arousal and promoting recovery of consciousness in some of these individuals.
=== October === 1 October – The European Southern Observatory (ESO) reports the discovery of a sub-Earth-mass planet orbiting Barnard's star, the closest single star to the Sun at six light-years away. 2 October Scientists announce the first ever complete mapping of the entire brain of a fruit fly, Drosophila melanogaster, with a detail of 50 million connections between more than 139,000 neurons. Scientists detect a new jet of carbon monoxide (CO) and previously unseen jets of carbon dioxide (CO2) gas on Centaur 29P by using the James Webb Space Telescope's Near-Infrared Spectrograph. 3 October – Google releases a new feature, "Video Search", which will allow people to ask a question while filming video of something, and get search results. 4 October – Scientists develop artificial plants with leaves using biological solar cells, which can perform respiration, photosynthesis and generate electricity. 7 October – Victor Ambros and Gary Ruvkun win the Nobel Prize in Physiology or Medicine "for the discovery of microRNA and its role in post-transcriptional gene regulation" 8 October Researchers at REMspace achieve the first communication between two individuals in lucid dreams using specially designed equipments. John Hopfield and Geoffrey Hinton win the Nobel Prize in Physics “for foundational discoveries and inventions that enable machine learning with artificial neural networks” 9 October Pham Tiep, a professor of mathematics, solves two long-standing problems, the Height Zero Conjecture and the Deligne-Lusztig theory.
Sources: en.wikipedia.org
=== Plant extracts === Most or all plants produce chemical insecticides to stop insects eating them. Extracts and purified chemicals from thousands of plants have been shown to be insecticidal, however only a few are used in agriculture. In the USA 13 are registered for use, in the EU 6. In Korea, where it is easier to register botanical pesticides, 38 are used. Most used are neem oil, chenopodium, pyrethrins, and azadirachtin. Many botanical insecticides used in past decades (e.g. rotenone, nicotine, ryanodine) have been banned because of their toxicity.
== Management == The treatment of obstructive sleep apnea is different from that of central sleep apnea. Treatment often starts with behavioral therapy and some people may be suggested to try a continuous positive airway pressure (CPAP) device. Many people are told to avoid alcohol, sleeping pills, and other sedatives, which can relax throat muscles, contributing to the collapse of the airway at night. The evidence supporting one treatment option compared to another for a particular person is not clear.
== Role == Central nervous system fatigue is a key component in preventing peripheral muscle injury. The brain has numerous receptors, such as osmoreceptors, to track dehydration, nutrition, and body temperature. With that information as well as peripheral muscle fatigue information, the brain can reduce the quantity of motor commands sent from the central nervous system. This is crucial in order to protect the homeostasis of the body and to keep it in a proper physiological state capable of full recovery. The reduction of motor commands sent from the brain increases the amount of perceived effort an individual experiences. By forcing the body through a higher perceived intensity, the individual becomes more likely to cease exercise by means of exhaustion. Perceived effort is greatly influenced by the intensity of corollary discharge from the motor cortex that affects the primary somatosensory cortex. Endurance athletes learn to listen to their body. Protecting organs from potentially dangerous core temperatures and nutritional lows is an important brain function. Central nervous system fatigue alerts the athlete when physiological conditions are not optimal so either rest or refueling can occur. It is important to avoid hyperthermia and dehydration, as they are detrimental to athletic performance and can be fatal.
Watson, Crick, Wilkins and Franklin all worked in MRC laboratories. Crick and Watson felt that they had benefited from collaborating with Wilkins. They offered him a co-authorship on the article that first described the double helix structure of DNA. Wilkins turned down the offer, a fact that may have led to the terse character of the acknowledgement of experimental work done at King's College in the eventual published paper. Rather than make any of the DNA researchers at King's College co-authors on the Watson and Crick double helix article, the solution that was arrived at was to publish two additional papers from King's College along with the helix paper. Brenda Maddox suggests that because of the importance of her experimental results in Watson and Crick's model building and theoretical analysis, Franklin should have had her name on the original Watson and Crick paper in Nature. Franklin and Gosling submitted their own joint "second" paper to Nature at the same time as Wilkins, Stokes, and Wilson submitted theirs (i.e. the "third" paper on DNA). Watson's portrayal of Franklin in The Double Helix was negative and gave the appearance that she was Wilkins' assistant and was unable to interpret her own DNA data. However, according to Nathaniel C. Comfort, a historian of medicine at Johns Hopkins University, Franklin's colleague Aaron Klug believed that Franklin "..was 'two steps away' from the double helix. After completing an analysis of her lab notebook, Klug stated that she surely would have had it.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.